[N:1]1([C:5]2[N:10]=[C:9]([CH2:11][CH3:12])[N:8]=[C:7]([NH:13][NH:14][C:15](=[O:35])[C@H:16]([CH2:29][CH:30]3[CH2:34][CH2:33][CH2:32][CH2:31]3)[CH2:17][N:18]([O:21]CC3C=CC=CC=3)[CH:19]=[O:20])[C:6]=2[F:36])[CH2:4][CH2:3][CH2:2]1>CO>[N:1]1([C:5]2[N:10]=[C:9]([CH2:11][CH3:12])[N:8]=[C:7]([NH:13][NH:14][C:15](=[O:35])[C@H:16]([CH2:29][CH:30]3[CH2:31][CH2:32][CH2:33][CH2:34]3)[CH2:17][N:18]([OH:21])[CH:19]=[O:20])[C:6]=2[F:36])[CH2:2][CH2:3][CH2:4]1[(2R)-3-{2-[6-(1-Azetidinyl)-2-ethyl-5-fluoro-4-pyrimidinyl]hydrazino}-2-(cyclopentylmethyl)-3-oxopropyl][(phenylmethyl)oxy]formamide (160 mg, 0.32 mmol) was dissolved in 10 mL of MeOH, degassed and placed under argon. 5% Pd/C (40 mg) was added, and the contents were thoroughly degassed and stirred under a hydrogen balloon until the reaction was deemed complete by LCMS. The contents were then degassed and filtered through Celite, and the Celite pad was washed with DCM and MeOH. The resulting filtrate was concentrated in vacuo to provide [(2R)-3-{2-[6-(1-azetidinyl)-2-ethyl-5-fluoro-4-pyrimidinyl]hydrazino}-2-(cyclopentylmethyl)-3-oxopropyl]hydroxyformamide (100 mg, 76%). LCMS: (M+H)+: 409.2.